Croda International (LSE:CRDA), the speciality chemicals group that makes high-performance ingredients for consumer and life sciences customers, reported organic sales growth of 4.6% for the six months to 30 June, with adjusted operating profit rising 6.7% to £155.8m from £146.9m a year earlier.
Consumer Care led the advance with 8% organic growth, powered by a 19% jump in Beauty Actives, while Life Sciences was flat as a 1% rise in Pharma offset a 2% decline in Crop.
Adjusted operating margin expanded to 17.7% from 17.2%, and IFRS operating profit rose to £115.5m from £94.4m, with free cash flow up 36.8% to £38.3m on lower capital expenditure.
"We have delivered a good first half performance in line with our expectations with strong growth in Consumer Care," said chief executive Steve Foots, adding that the group is "rigorously executing our plan to grow earnings and returns" while reinvigorating Beauty and rebalancing Pharma.
Net leverage eased to 1.4 times EBITDA from 1.5 times, and the board held the interim dividend flat at 48.0p as it works to restore dividend cover.
Croda delivered £18m of incremental transformation savings in the period, part of a plan targeting roughly £100m of efficiency benefits and £50m of working capital improvements by 2028.
The group left its full-year 2026 guidance unchanged, still expecting organic sales growth within its 3-6% range and further adjusted operating margin expansion, with a third-quarter trading update due on 5 November.
News Intelligence what this means for the company
Croda delivered H1 organic growth of 4.6% with Consumer Care accelerating at 8%, but Life Sciences stalled as pharma gains were offset by crop weakness. The company maintained its full-year 2026 guidance (3–6% organic growth, further margin expansion) and improved cash generation 36.8% to £38.3m, signalling execution on its efficiency plan but offering no upside surprise to reset investor expectations.
The results confirm Croda is tracking to plan rather than breaking out: Consumer Care momentum is real (Beauty Actives +19%), but Life Sciences flatness and a held dividend at 48.0p—while net leverage eased to 1.4x EBITDA—suggest the company is prioritising balance-sheet repair over shareholder returns. Unchanged full-year guidance leaves no room for positive revision unless Q3–Q4 accelerates materially.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
